Shira Dinner

3.3k total citations
67 papers, 727 citations indexed

About

Shira Dinner is a scholar working on Hematology, Genetics and Molecular Biology. According to data from OpenAlex, Shira Dinner has authored 67 papers receiving a total of 727 indexed citations (citations by other indexed papers that have themselves been cited), including 49 papers in Hematology, 28 papers in Genetics and 19 papers in Molecular Biology. Recurrent topics in Shira Dinner's work include Acute Myeloid Leukemia Research (36 papers), Chronic Lymphocytic Leukemia Research (19 papers) and Chronic Myeloid Leukemia Treatments (18 papers). Shira Dinner is often cited by papers focused on Acute Myeloid Leukemia Research (36 papers), Chronic Lymphocytic Leukemia Research (19 papers) and Chronic Myeloid Leukemia Treatments (18 papers). Shira Dinner collaborates with scholars based in United States, Australia and Canada. Shira Dinner's co-authors include Michaela Liedtke, Leonidas C. Platanias, Adam Yuh Lin, Richard Lafayette, Sally Arai, Ronald Witteles, Elizabeth Rich, Wendy Stock, Eunice S. Wang and Madelyn Burkart and has published in prestigious journals such as JAMA, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Shira Dinner

63 papers receiving 714 citations

Peers

Shira Dinner
Susana Vives Spain
Bhavana Bhatnagar United States
Elliot Stieglitz United States
Kelly S. Chien United States
Jochen Casper Germany
Anna Mestice Italy
C. Michel Zwaan Netherlands
Jason H. Mendler United States
Emily Curran United States
Vladan Vučinić Germany
Susana Vives Spain
Shira Dinner
Citations per year, relative to Shira Dinner Shira Dinner (= 1×) peers Susana Vives

Countries citing papers authored by Shira Dinner

Since Specialization
Citations

This map shows the geographic impact of Shira Dinner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shira Dinner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shira Dinner more than expected).

Fields of papers citing papers by Shira Dinner

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shira Dinner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shira Dinner. The network helps show where Shira Dinner may publish in the future.

Co-authorship network of co-authors of Shira Dinner

This figure shows the co-authorship network connecting the top 25 collaborators of Shira Dinner. A scholar is included among the top collaborators of Shira Dinner based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shira Dinner. Shira Dinner is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Alvarado, Yesid, Rachel J. Cook, Shira Dinner, et al.. (2025). The oral CDK9 inhibitor voruciclib combined with venetoclax for patients with relapsed/refractory acute myeloid leukemia. PubMed. 2(3). 100108–100108. 1 indexed citations
2.
Cortes, Jörge E., Jay Yang, Gail J. Roboz, et al.. (2025). Olutasidenib alone or combined with azacitidine in patients with mutant IDH1 myelodysplastic syndrome. Blood Advances. 9(20). 5293–5305. 1 indexed citations
3.
4.
Palmisiano, Neil, Ju‐Whei Lee, David F. Claxton, et al.. (2024). A phase 1 trial of venetoclax in combination with liposomal vincristine in patients with relapsed or refractory B‐cell or T‐cell acute lymphoblastic leukemia: Results from the ECOG‐ACRIN EA9152 protocol. SHILAP Revista de lepidopterología. 5(5). 951–956. 1 indexed citations
5.
Dinner, Shira, et al.. (2024). Dosing of 7 + 3 induction chemotherapy in a patient with acute myeloid leukemia (AML) and morbid obesity. Journal of Oncology Pharmacy Practice. 30(5). 945–949. 1 indexed citations
6.
Wang, Eunice S., Jörge E. Cortes, Justin M. Watts, et al.. (2024). Time to Response and Overall Survival in Patients with mIDH1 Relapsed/Refractory Acute Myeloid Leukemia Treated with Olutasidenib. Blood. 144(Supplement 1). 1514–1514.
7.
Jain, Akriti, Madelyn Burkart, Xiaoyue Ma, et al.. (2024). Assessing Role of Comorbidities in Treatment Selection for Older Patients with Acute Myeloid Leukemia. Blood. 144(Supplement 1). 2867–2867.
8.
Burkart, Madelyn & Shira Dinner. (2024). Advances in the treatment of Philadelphia chromosome negative acute lymphoblastic leukemia. Blood Reviews. 66. 101208–101208. 1 indexed citations
9.
Davids, Matthew S., Danielle M. Brander, Yesid Alvarado, et al.. (2024). A phase 1 study of the CDK9 inhibitor voruciclib in relapsed/refractory acute myeloid leukemia and B-cell malignancies. Blood Advances. 9(4). 820–832. 3 indexed citations
10.
11.
Wieduwilt, Matthew J., Jun Yin, Rebecca Teske, et al.. (2023). Chemotherapy-free treatment with inotuzumab ozogamicin and blinatumomab for older adults with newly diagnosed, Ph-negative, CD22-positive, B-cell acute lymphoblastic leukemia: Alliance A041703.. Journal of Clinical Oncology. 41(16_suppl). 7006–7006. 22 indexed citations
12.
Badar, Talha, Mark R. Litzow, Rory M. Shallis, et al.. (2022). Disparities in receiving disease‐directed therapy, allogeneic stem cell transplantation in non‐Hispanic Black patients with TP53‐mutated acute myeloid leukemia. Cancer. 129(6). 934–945. 5 indexed citations
13.
Jain, Akriti, Madelyn Burkart, Christopher Famulare, et al.. (2021). Comparing Outcomes between Liposomal Daunorubicin/Cytarabine (CPX-351) and HMA+Venetoclax As Frontline Therapy in Acute Myeloid Leukemia. Blood. 138(Supplement 1). 32–32. 13 indexed citations
14.
Gao, Juehua, Madelyn Burkart, Masha Kocherginsky, et al.. (2020). Therapy-related B-cell acute lymphoblastic leukemia in adults has unique genetic profile with frequent loss of TP53 and inferior outcome. Leukemia. 35(7). 2097–2101. 8 indexed citations
15.
16.
Cortes, Jörge E., Justin M. Watts, Thomas Prébet, et al.. (2018). FT-2102, an IDH1m Inhibitor, in Combination with Azacitidine in Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Ayndrome (MDS): Results from a Phase 1 Study. Blood. 132(Supplement 1). 1452–1452. 14 indexed citations
17.
Dinner, Shira, Elizabeth Price, Steven Coutré, et al.. (2018). A phase I, open-label, dose-escalation study of amrubicin in combination with lenalidomide and weekly dexamethasone in previously treated adults with relapsed or refractory multiple myeloma. International Journal of Hematology. 108(3). 267–273. 1 indexed citations
18.
Choi, Sarah M., Benjamin Goldenson, Lo Ann C. Peterson, et al.. (2017). Diagnostic and therapeutic implications of genetic heterogeneity in myeloid neoplasms uncovered by comprehensive mutational analysis. Leukemia Research Reports. 8. 11–13. 1 indexed citations
19.
Liedtke, Michaela, Shira Dinner, Steven Coutré, et al.. (2014). Salvage therapy with mitoxantrone, etoposide and cytarabine in relapsed or refractory acute lymphoblastic leukemia. Leukemia Research. 38(12). 1441–1445. 12 indexed citations
20.
Dinner, Shira, Daniel J. Lee, & Michaela Liedtke. (2013). Current therapy and novel agents for relapsed or refractory acute lymphoblastic leukemia. Leukemia & lymphoma. 55(8). 1715–1724. 22 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Susana Vives Breakdown of academic impact, for papers by Bhavana Bhatnagar Breakdown of academic impact, for papers by Elliot Stieglitz Breakdown of academic impact, for papers by Kelly S. Chien Breakdown of academic impact, for papers by Jochen Casper Breakdown of academic impact, for papers by Anna Mestice Breakdown of academic impact, for papers by C. Michel Zwaan Breakdown of academic impact, for papers by Jason H. Mendler Breakdown of academic impact, for papers by Emily Curran Breakdown of academic impact, for papers by Vladan Vučinić
Rankless by CCL
2026